Clinical trial
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
NCT00530348
Study timeline
Study start (unknown)2007-08-01Date precision: month
Registry last updated2014-11-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosis, Relapsing-Remittingunresolved
Interventions
AlemtuzumabBIOLOGICAL
Interferon beta-1aBIOLOGICAL
Sponsors & collaborators
Genzyme, a Sanofi Companylead sponsor
Bayercollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00530348 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.